Abstract: The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.

Abstract: The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.

Abstract: A method for cryptographic key provisioning includes, via a main authentication server (MAS), generating a first secret key and registering a client by performing a first portion of a first instance of a distributed threshold oblivious pseudo-random function. The first instance of the function results in the client obtaining a root secret key and the MAS obtaining a corresponding root public key. The method includes authenticating the client to the MAS by performing a first portion of a second instance of the distributed threshold oblivious pseudo-random function. The second instance of the function results in the client obtaining the root secret key. Information stored by the client, the first secret key, and a second secret key generated by a support authentication server are inputs to at least one of the first and second instances of the distributed threshold oblivious pseudo-random function.

Abstract: A method for anonymous authentication and key establishment based on passwords (APAKE), includes instantiating, by the server, an OPRF scheme and a symmetric encryption scheme; engaging in, by the client and the server, an OPRFEvaluate protocol so that the client learns a decryption key associated with its password while the server learns nothing; securely transferring, by the server, a nonce and a symmetric encryption key to the client if the client holds a valid password; sending, by the client, its nonce encrypted under the symmetric encryption key; using, by the server, the symmetric encryption key to decipher ciphertext received by virtue of the sending, by the client, its nonce encrypted under the symmetric encryption key and to recover the client's nonce; and computing, by the server and the client, a compute key based on the client's nonce and the server's nonce.

Abstract: A method for cryptographic key provisioning includes, via a main authentication server (MAS), generating a first secret key and registering a client by performing a first portion of a first instance of a distributed threshold oblivious pseudo-random function. The first instance of the function results in the client obtaining a root secret key and the MAS obtaining a corresponding root public key. The method includes authenticating the client to the MAS by performing a first portion of a second instance of the distributed threshold oblivious pseudo-random function. The second instance of the function results in the client obtaining the root secret key. Information stored by the client, the first secret key, and a second secret key generated by a support authentication server are inputs to at least one of the first and second instances of the distributed threshold oblivious pseudo-random function.

Abstract: The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.

Abstract: A method for anonymous authentication and key establishment based on passwords (APAKE), includes instantiating, by the server, an OPRF scheme and a symmetric encryption scheme; engaging in, by the client and the server, an OPRFEvaluate protocol so that the client learns a decryption key associated with its password while the server learns nothing; securely transferring, by the server, a nonce and a symmetric encryption key to the client if the client holds a valid password; sending, by the client, its nonce encrypted under the symmetric encryption key; using, by the server, the symmetric encryption key to decipher ciphertext received by virtue of the sending, by the client, its nonce encrypted under the symmetric encryption key and to recover the client's nonce; and computing, by the server and the client, a compute key based on the client's nonce and the server's nonce.

Abstract: A Kluyveromyces lactis yeast strain comprising the sequence identified by SEQ ID NO: 1, and methods for the production of sugars (glucose and galactose), ethanol, ?-galactosidase and biomass is provided, in which the Kluyveromyces lactis yeast strain is cultured in the presence of a lactose-containing medium. The lactose-containing medium may be milk, whey, whey resulting from the preparation of butter, whey resulting after casein precipitation, milk permeate, whey permeate, acid whey and YPL culture medium.

Abstract: The present invention is a Kluyveromyces lactis yeast strain comprising the sequence identified by SEQ ID NO: 1, and methods for the production of sugars (glucose and galactose), ethanol, ?-galactosidase and biomass, in which said Kluyveromyces lactis yeast strain is cultured in the presence of a lactose-containing medium. The lactose-containing medium may be milk, whey, whey resulting from the preparation of butter, whey resulting after casein precipitation, milk permeate, whey permeate, acid whey and YPL culture medium.

Abstract: The invention relates to strains of S. cerevisiae capable of secreting ?-galactosidase into culture medium, as well as to methods for obtaining ?-galactosidase using said strains and methods for producing biomass and bioethanol by means of culturing said strains in media rich in galactose. In another aspect, the invention provides methods for expressing recombinant proteins using a composition rich in galactose as a culture medium for the microorganisms producing said protein.

Abstract: Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.

Abstract: Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.

Abstract: Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females.